Skip to content

Search for Studies

Search Results

The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function

Conditions:
Moderate to Severe Asthma
Location:
  • Centre For Lung Health, Vancouver, British Columbia, Canada
  • Dr. Syed Anees Medicine Professional Corporation, Windsor, Ontario, Canada
  • Dynamic Drug Advancement, Ajax, Ontario, Canada
  • Synergy Respiratory Care, Sherwood Park, Alberta, Canada
  • S. Fikry Medicine Professional Corporation, Waterloo, Ontario, Canada
  • Ottawa Allergy Research Corporation, Ottawa, Ontario, Canada
Sex:
ALL
Ages:
18 - 65

The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.

Conditions:
Multiple Myeloma
Location:
  • Tom Baker Cancer Center, Calgary, Alberta, Canada
  • McGill University Health Centre, Montreal, Quebec, Canada
Sex:
ALL
Ages:
Over 18

Testicular cancer represents 1% of adult neoplasms and is the most common solid malignancy in young men. At diagnosis, approximately 90% of cases are germ cell tumours (GCT), categorised as either seminoma (55-60%) or non-seminoma types (40-45%). For many years, the management of patients with CS IIA/B seminoma and retroperitoneal lymph node involvement ≤ 3 cm are eligible for treatment with either radiotherapy or chemotherapy Despite high cure rates for CS II seminoma (approximately 90%) with chemotherapy or radiotherapy, concerns persist regarding short and long-term treatment-related toxicities (such as increased risks of cardiovascular disease and secondary malignancies As such, an alternative strategy which has been explored in this study is the role of RPLND for the management of these patients

Conditions:
Testicular Cancer
Location:
  • London Health Sciences Centre, London, Ontario, Canada
Sex:
MALE
Ages:
Over 18

This is a single centre, interventional, randomized Phase II, two-arm prospective trial investigating if Stereotactic Body Radiotherapy (SBRT) to all sites of Oligopressive (OP) disease while remaining on current Systemic Therapy (ST) will improve biochemical control compared to Standard of Care (SoC) (which involves a change in ST) for patients with OP Castrate Resistance Prostate Cancer (CRPC).

Conditions:
OligoProgressive Metastatic Disease | Castrate Resistance Prostate Cancer
Location:
  • Princess Margaret Cancer Center, Toronto, Ontario, Canada
Sex:
MALE
Ages:
18 - 100

The purpose of this study is to assess the feasibility and acceptability of providing oral pre-exposure prophylaxis (PrEP) and opioid agonist therapy (OAT) simultaneously in existing pharmacy-based programs operating in Alberta and Saskatchewan, to collect preference, adherence, and persistence data on oral PrEP, and to assess interest / acceptability of long-lasting injectable options for human immunodeficiency virus (HIV) prevention.

Conditions:
HIV - Human Immunodeficiency Virus
Location:
  • Pharmasave Riversdale Pharmacy, Saskatoon, Saskatchewan, Canada
  • Queen City Wellness Pharmacy, Regina, Saskatchewan, Canada
  • Meadowgreen Pharmacy, Saskatoon, Saskatchewan, Canada
  • Mayfair Drugs Pharmacy, Saskatoon, Saskatchewan, Canada
  • Sheldon M Chumir Health Centre, Calgary, Alberta, Canada
  • The Medicine Shoppe Pharmacy, Saskatoon, Saskatchewan, Canada
Sex:
ALL
Ages:
Over 16

Levator ani muscle is one of the main components of perineal muscles and plays a crucial role in urinary continence and pelvic organ support. An avulsion, detachment from its insertion, of this muscle can occur during vaginal birth. It is well known that this major injury can cause many symptoms such as urinary incontinence and pelvic organ prolapses. Some risk factors of this important injury have been identified in the literature, such as the use of forceps. However, to date, no study has evaluated the impact of the crowning of the fetal head during labor on perineal muscles, specifically the levator ani muscle avulsion. Hence, the objectives of this study are to evaluate the association i) the time of the crowning of the fetal head during labor and levator ani muscle avulsion, ii) the time of the crowning of the fetal head and urogynecological symptoms, and iii) use of episiotomy and levator ani muscle avulsion. Postpartum primiparous women will undergo a 4D transperineal ultrasound to evaluate their pelvic muscles and complete questionnaires assessing urogynecological symptoms.

Conditions:
Postpartum | Levator Ani Avulsion | Labor Delivery | Time of the Crowning of the Fetal Head
Location:
  • CHUS Fleurimont, Sherbrooke, Quebec, Canada
Sex:
FEMALE
Ages:
Over 18

The purpose of the Non-Alcoholic Fatty Liver Disease (NAFLD) registry is to collect demographic and clinical data on patients being treated for NAFLD and to determine the factors affecting the progression of the disease as well as the success of different treatment strategies.

Conditions:
Non-Alcoholic Fatty Liver Disease
Location:
  • Toronto General Hospital, Toronto, Ontario, Canada
Sex:
ALL
Ages:
Over 18

This study aims to investigate the optimal oxygen flow rate needed during tracheal intubation with the C-MAC video laryngoscope (Karl Storz, Tuttlingen, Germany) using Miller-blade or Macintosh-blade size No. 0 or No. 1 in the operating room or intensive care unit. The investigators hypothesize that the difference between low-flow and high-flow supplemental oxygen is negligible.

Conditions:
Airway Management
Location:
  • Dept. Anesthesia, The Hospital for Sick Children, Toronto, Ontario, Canada
Sex:
ALL
Ages:
Under 52

This research is being conducted to evaluate emotion-focused therapy that incorporates elements of mindfulness, distress tolerance, and relationship support. The investigators want to learn if this therapy, called Dialectical Behavioral Therapy (DBT) will help improve quality of life and weight management in youth at risk for type 2 diabetes. Individuals will be randomly assigned to weekly group based session in one of 3 intervention arms; lifestyle + DBT, lifestyle alone, or a control arm.

Conditions:
Prevention | Type2Diabetes
Location:
  • University of Calgary, Calgary, Alberta, Canada
  • McMaster University, Hamilton, Ontario, Canada
  • University of Manitoba, Winnipeg, Manitoba, Canada
Sex:
ALL
Ages:
14 - 17

In this study, researchers want to learn about the safety of a new drug, BAY 3547926, and how well the drug works in people with a type of liver cancer called advanced hepatocellular carcinoma (HCC), which has a special protein called Glypican 3 (GPC3). Researchers want to find the best dose of BAY 3547926 for people with advanced HCC and look at the way the body absorbs and distributes the drug. The study drug, BAY 3547926, delivers a radioactive agent to cancer cells. The radioactive agent emits radiations which can damage the cancer cells and cause them to die. These radiations travel a small distance, so are expected to cause little damage to surrounding healthy tissues. This is the first study of BAY 3547926 in humans. Participants will take part in one of the 3 different parts of the study. In Part 1, participants will receive different doses of BAY 3547926 alone to find the dose that is deemed safe and works best for the participants. When this dose has been found, a larger number of participants will receive BAY 3547926 alone in Part 2 or with other treatments in Part 3 of the study. During the study, the doctors and their study team will do health check-ups, take pictures (scans) of the body, collect blood and urine samples, and ask participants questions about how they are feeling and what health problems they are having.

Conditions:
Hepatocellular Carcinoma
Location:
  • Juravinski Cancer Centre - Clinical Trials Department, Hamilton, Ontario, Canada
  • CIUSSS de l'Estrie-CHUS, Sherbrooke, Quebec, Canada
  • University of Alberta - Cross Cancer Institute (CCI), Edmonton, Alberta, Canada
  • McGill University Health Centre (MUHC) - Research Institute (RI) - McConnell Centre for Innovative Medicine (CIM), Montreal, Quebec, Canada
  • Centre Hospitalier de l'Universite de Montreal (CHUM) - Hopi, Montreal, Quebec, Canada
Sex:
ALL
Ages:
Over 18